Sökning: "Pancreatic ductal adenocarcinoma PDAC"

Visar resultat 1 - 5 av 26 avhandlingar innehållade orden Pancreatic ductal adenocarcinoma PDAC.

  1. 1. Repurposing digitoxin in the treatment of pancreatic ductal adenocarcinoma : genotypic and phenotypic features as biomarkers for digitoxin sensitivity in vitro

    Författare :Heléne Lindholm; Katarina Ejeskär; Ferenc Szekeres; Maria Faresjö; Sofie Mohlin; Högskolan i Skövde; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; pancreatic ductal adenocarcinoma; Na K -ATPase; digitoxin; cardiac glycoside; metabolomics; choline; Translationell medicin TRIM; Translational Medicine TRIM;

    Sammanfattning : The incidence of pancreatic ductal adenocarcinoma (PDAC) is increasing worldwide. The dismal prognosis and lack of effective treatments urges for increased research efforts in developing new treatment regimens. Since the development of new cancer treatments are expensive and time consuming, repurposing drugs is preferable when possible. LÄS MER

  3. 2. In search of early biomarkers in pancreatic ductal adenocarcinoma using multi-omics and bioinformatics

    Författare :Emmy Borgmästars; Malin Sund; Ola Billing; Pär Jonsson; Zelmina Lubovac-Pilav; Oskar Franklin; Stefan Enroth; Umeå universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; NATURVETENSKAP; NATURAL SCIENCES; Pancreatic cancer; microRNA functional analysis; TPS; miRNomics; metabolomics; proteomics; plasma samples; early detection; risk; survival;

    Sammanfattning : Background: Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive malignancy with a 5-year survival of 10 %. Surgery is the only curative treatment. Unfortunately, few patients are eligible for surgery due to late detection. Thus, we need ways to detect the disease at an earlier stage and for that good screening biomarkers could be used. LÄS MER

  4. 3. The identification and functional evaluation of novel cancer-associated fibroblast subtypes and matrisome proteins in pancreatic cancer

    Författare :Joshua Cumming; Daniel Öhlund; Cedric Patthey; Jenny Persson; Claus Jørgensen; Umeå universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Cancer-associated fibroblast CAF ; Single-cell RNA sequencing scRNAseq ; Pancreatic ductal adenocarcinoma PDAC ; Tumor microenvironment TME ; Extracellular matrix ECM ; Organoid-based co-culture model; Drug-screen; Oncology; onkologi;

    Sammanfattning : Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by an extensive desmoplastic stroma. The stroma is the site of intricate communication between malignant cells and their surrounding environment. LÄS MER

  5. 4. Characterizing the pancreatic "isletome" : 3D optical imaging to study diabetes

    Författare :Max Hahn; Ulf Ahlgren; András Gorzsás; Leif Carlsson; Alvin C. Powers; Umeå universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; 3D imaging; fluorescence microscopy; 3D image analysis; technique development; diabetes; Islet of Langerhans; Insulin; β-cell mass; pancreas; anatomy; molecular medicine medical sciences ; molekylär medicin medicinska vetenskaper ; medicinsk biokemi; Medical Biochemistry;

    Sammanfattning : The pancreas is a specialised multipurpose organ, that can be separated into two major compartments: endocrine and exocrine. The exocrine part makes up the majority of the organ volume and functions to secrete digestive enzymes into the small intestine. LÄS MER

  7. 5. Pancreatic ductal adenocarcinoma : computed tomography for diagnosis, local staging and prediction of postoperative complications

    Författare :Louiza Loizou; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : Pancreatic ductal adenocarcinoma (PDAC) is a disease with a dismal prognosis, being the 4th leading cause of cancer deaths in Sweden and worldwide. The only potentially curative therapy is surgery. Unfortunately, by the time of diagnosis only 20% of patients have a resectable tumor and the overall 5-year survival rate does not exceed 5%. LÄS MER